Hexarelin: Complete Research Guide — GHRP-6 Analog, Dual GHS-R1a + CD36 Cardiac Receptor Activity & Human Data (2026)

What Is Hexarelin and How Does It Differ from Other GH Secretagogues?

Hexarelin (CAS: 140703-51-1; IUPAC: His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GH-releasing peptide (GHRP) developed by Roberto Deghenghi, Bruno Imbimbo and colleagues at Europeptides/Mediolanum Farmaceutici in Italy during the early 1990s. Updated April 2026. The compound is structurally derived from GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) with a single critical modification: the substitution of D-tryptophan at position 2 with 2-methyl-D-tryptophan. This methylation increases hydrophobicity and GHS-R1a receptor binding affinity, making hexarelin more potent than GHRP-6 on a molar basis and more resistant to peptidase degradation. Deghenghi et al. (1994) first characterized hexarelin’s GH-releasing activity across intravenous, subcutaneous, intranasal, and oral administration routes in humans — an early multi-route pharmacology study that established its clinical tractability.

What most distinguishes hexarelin from Ipamorelin and other GHRPs in the YPB catalog is not its GHS-R1a potency, but its second receptor: CD36. Ong et al. (1998–1999) identified CD36 as a specific cardiac receptor for hexarelin — a binding site present in cardiac and vascular tissue that mediates cardioprotective effects independently of GH secretion. This dual receptor profile makes hexarelin a unique research tool for studying both the pituitary GH axis and direct cardiac peptide signaling through separate, non-overlapping pathways.

Key Characteristics

How Does Hexarelin Work? Dual Receptor Mechanism

Hexarelin’s pharmacological profile is defined by two distinct receptor systems. Understanding both is essential for designing appropriate research protocols and for distinguishing hexarelin from other GH secretagogues.

Mechanism 1: GHS-R1a Agonism (Pituitary GH Release)

Hexarelin binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor activated by ghrelin, GHRP-6, and Ipamorelin. GHS-R1a is expressed in pituitary somatotroph cells, the hypothalamus, and peripherally. Activation of GHS-R1a stimulates GH release via Gq/11-protein signaling (IP3/DAG/PKC pathway) and calcium mobilization in somatotroph cells, synergizing with GHRH receptor signaling to amplify GH pulse amplitude. Hexarelin’s 2-methyl-D-Trp2 modification increases its GHS-R1a binding affinity above that of GHRP-6, making it the most potent hexapeptide GHRP at this receptor in the YPB catalog.

Published data comparing hexarelin to other GHRPs documents higher peak GH responses per unit dose compared to GHRP-6, reflecting its higher GHS-R1a affinity. The GHS-R1a mechanism is shared with Ipamorelin (see the Ipamorelin Research Guide), though hexarelin is non-selective while Ipamorelin was specifically designed as the first selective GH secretagogue without cortisol or prolactin co-stimulation.

Mechanism 2: CD36 Agonism (Direct Cardiac Activity)

The defining mechanistic distinction of hexarelin is its activity at CD36 (cluster of differentiation 36; also known as fatty acid translocase, FAT). Ong et al. identified CD36 as a specific hexarelin-binding receptor in cardiac and vascular tissue in 1998–1999 — a receptor entirely distinct from GHS-R1a and from all GHRH-class receptors. CD36 is expressed in cardiomyocytes, endothelial cells, and vascular smooth muscle. Its activation by hexarelin mediates cardioprotective effects via protein kinase C (PKC) signaling, independently of GH secretion or IGF-1 elevation (Ong et al., Endocrinology, 1998 — PMID: 10532947).

The CD36 mechanism explains why hexarelin produces cardioprotective effects in GH-deficient animal models where the GH/IGF-1 axis is absent — the cardiac protection cannot be attributed to GH-mediated growth, and therefore must be mediated by direct CD36-PKC signaling. This makes hexarelin a unique research tool for studying direct cardiac peptide receptor biology independently of systemic GH/IGF-1 effects.

Tachyphylaxis: A Key Pharmacological Consideration

Published data for hexarelin consistently documents GH response attenuation with continuous or high-frequency administration — a tachyphylaxis pattern not observed to the same degree with Ipamorelin. Studies spanning extended administration periods show progressive reduction in GH response amplitude, attributed to GHS-R1a desensitization and downregulation. Published research protocols studying hexarelin’s GH-releasing effects therefore typically use pulsatile, intermittent dosing rather than continuous administration. Researchers designing hexarelin protocols should account for tachyphylaxis in their experimental design; it does not affect the CD36 cardiac mechanism, which operates through a separate receptor.

What Systems Has Hexarelin Been Investigated For?

Hexarelin’s published research applications span GH secretagogue biology, cardiac protection research, GH deficiency models, and the pharmacology of the GHS-R1a / CD36 receptor systems.

GH Axis and Somatotroph Research

Hexarelin’s early characterization established it as a potent GH secretagogue across multiple administration routes. Deghenghi et al. (1994) documented GH-releasing activity via intravenous, subcutaneous, intranasal, and oral routes, establishing its multi-route pharmacological profile. Comparative studies with GHRP-6 confirmed hexarelin’s superior potency at GHS-R1a. Hexarelin synergizes with GHRH (the endogenous ligand of GHRHR) in GH release, producing supra-additive responses in published co-administration studies — consistent with the two-receptor (GHS-R1a + GHRHR) amplification model.

Cardiac Protection Research

The CD36-mediated cardioprotective research profile of hexarelin is the most clinically distinctive published application. Tivesten et al. (2000) published data in Endocrinology demonstrating that hexarelin improved cardiac function in rats following experimental myocardial infarction — including improvements in cardiac output and reduced post-MI cardiac dysfunction. Critically, these cardiac effects were observed in GH-deficient animals where systemic GH/IGF-1 effects could not account for the improvement, providing the key evidence that CD36-mediated direct cardiac activity is the mechanism.

De Gennaro Colonna et al. (1997) documented protectant activity against cardiovascular damage in GH-deficient rats. Additional published data demonstrates hexarelin inhibits cardiomyocyte apoptosis via CD36-PKC signaling, reduces infarct size in ischemia-reperfusion models, and attenuates cardiac fibrosis in hypertension models. The cardiovascular research program for hexarelin represents the most extensive published cardiac data for any GH secretagogue in the YPB catalog.

Human Cardiac Function Research

Bisi et al. (1999) published a human study in 7 male volunteers examining cardiac performance by radionuclide angiocardiography after IV administration of hexarelin versus recombinant GH. The study documented that both hexarelin and rhGH increased GH levels to similar extents, but hexarelin produced distinct cardiovascular effects. This human cardiac pharmacodynamic data — while small-N — represents published in-human documentation of hexarelin’s cardiac activity beyond its GH-releasing profile (Bisi et al., J Endocrinol Invest, 1999 — PMID: 10342360).

What Does the Human Research Data Show So Far?

Hexarelin has been evaluated in multiple human studies, though the available evidence is primarily Phase 1/pharmacokinetic characterization and small-N mechanistic studies rather than large-scale RCTs.

Human Safety Summary

A key published finding from the Bisi et al. (1999) human study is that hexarelin, unlike Ipamorelin, does produce cortisol elevation via GHS-R1a at IV doses studied — a non-selectivity characteristic that distinguishes it from the selective GH secretagogue profile. Researchers comparing hexarelin to Ipamorelin should account for this difference in HPA axis engagement. No large-scale RCT for hexarelin has been published; the available human data is primarily pharmacokinetic and pharmacodynamic characterization. All YPB hexarelin is Research Use Only and is not equivalent to any approved compound product.

How Does Hexarelin Compare to Other GH Secretagogues?

Hexarelin occupies a distinct position within the GHS class: the highest-potency GHRP in the YPB catalog with the unique addition of CD36 cardiac receptor activity and a documented tachyphylaxis profile that requires pulsatile dosing protocols.

For researchers requiring a GHRP with maximum GHS-R1a potency and without concern about cortisol co-stimulation, hexarelin is the catalog-leading choice. For researchers requiring a selective GH secretagogue without HPA axis engagement, the Ipamorelin Research Guide covers the selective alternative. For long-acting GHRH-class research, the CJC-1295 with DAC Research Guide covers the 6–8 day albumin-binding analog.

What Should Researchers Know About Hexarelin Stability and Handling?

Hexarelin at 887.05 Da is a mid-weight hexapeptide. The 2-methyl-D-Trp2 substitution that distinguishes it from GHRP-6 improves metabolic stability by increasing resistance to aminopeptidase cleavage at the N-terminal position, contributing to a longer effective half-life than GHRP-6.

Storage and Reconstitution Protocol

Lyophilized hexarelin is stable at −20°C for up to 24 months when protected from moisture and light. Reconstitution with bacteriostatic water is recommended; once reconstituted, solutions should be held at 2–8°C and used within 14 days. Hexarelin is supplied as the acetate salt (MW 949.11 Da) in lyophilized form, which is the standard compound presentation for GHRPs. Avoid repeated freeze-thaw cycles.

COA Verification

HPLC purity (≥98%) combined with mass spectrometry confirmation at 887.05 Da (free base) or 949.11 Da (acetate salt) is the standard quality protocol. The D-amino acid configuration at positions 2 (D-2-methyl-Trp) and 5 (D-Phe) is critical for GHS-R1a binding specificity and should be confirmed by chiral HPLC or retention time comparison against a standard. All YPB hexarelin batches include lot-traceable COA documentation accessible through the COA Library.

Key Research Findings: Hexarelin in 2026

Market Demand and Research Interest

Hexarelin generates approximately 9,000 monthly US searches, driven by research interest in the highest-potency GHRP class and by the compound’s distinctive CD36 cardiac research profile. The cardiac protection narrative is unusual in the GH secretagogue category and attracts a research audience distinct from standard GH axis researchers.

Market Demand Indicators

How Can Researchers Offer Hexarelin Under Their Own Brand?

YourPeptideBrand.com provides white-label dropship for hexarelin in a 5mg configuration. Its dual GHS-R1a + CD36 mechanism, highest GHRP potency in the catalog, and unique cardiac research narrative differentiate it clearly from Ipamorelin and CJC-1295 in the GH-axis category.

Hexarelin Wholesale Pricing & Margin Analysis

Use the YPB Profit Calculator to model projected monthly revenue. Hexarelin at Premier tier generates $86.73 gross margin per unit at $130 MSRP (67%) — the highest per-unit margin in the GH secretagogue subcategory and among the strongest margin profiles in the full catalog. White-label brands with strong GH-axis research content can position hexarelin alongside Ipamorelin as a comparative GHRP pair — selective vs. non-selective GHS-R1a profiles — capturing both research buyer segments from a single GH secretagogue content investment. Download the full catalog for complete GH-axis SKU pricing.

Methodology & Data Sources

References

Frequently Asked Questions

Key Takeaways

Research Takeaways

• CD36 cardiac receptor: the defining differentiator. Hexarelin is the only GH secretagogue with documented CD36 activity — Ong et al. (1998–1999, PMID: 10532947) identified CD36 as a specific hexarelin receptor in cardiac tissue mediating PKC-dependent cardiomyocyte protection independently of GH.
• Post-MI cardiac improvement in GH-deficient models: Tivesten et al. (2000) confirmed hexarelin improved cardiac function after experimental MI in rats where GH/IGF-1 could not account for the effect — direct CD36 mechanism confirmed.
• Highest GHS-R1a potency among YPB GHRPs: 2-methyl-D-Trp2 substitution produces superior GH release vs. GHRP-6; comparative data documents higher peak GH per unit dose.
• Non-selective profile: Unlike Ipamorelin, hexarelin co-stimulates cortisol and can stimulate prolactin via GHS-R1a; researchers requiring selective GH-only stimulation should use Ipamorelin.
• Tachyphylaxis requires pulsatile protocols: GHS-R1a desensitization with continuous dosing is consistently documented; intermittent administration is the published protocol standard for hexarelin GH research.
• Human data published: Multi-route PK (1994), n=7 cardiac study (Bisi 1999, PMID: 10342360), HPA axis characterization; no large-scale RCT available.
• D-amino acid verification critical in COA: D-2-methyl-Trp2 and D-Phe5 are essential for GHS-R1a affinity; chiral HPLC confirmation required in quality-critical applications.

Business Takeaways

• $86.73 gross margin per unit at Premier tier (67%) — highest margin in the GH secretagogue subcategory; CD36 + cardiac research narrative supports $130 MSRP premium over Ipamorelin.
• ~9,000 monthly searches at low KD — dual GH research and cardiac research audiences from a single compound.
• No content overlap with Ipamorelin guide: The CD36 cardiac mechanism and non-selective HPA axis profile are entirely distinct from Ipamorelin’s selective GH-only narrative; both guides can coexist in a catalog without competing for the same research buyer.
• Hexarelin + Ipamorelin comparative pair captures the full GH secretagogue research market — selective and non-selective — at $180+ combined margin per dual-order.

Ready to add hexarelin to your research catalog? Book a consultation with the YPB team.

[ypb_studies peptide=”hexarelin”]